Amgen Builds Up Future Launches As Oncology Biosimilars Slide

Firm Looks To Amjevita, Along With Stelara And Eylea Rivals, For Future Growth

 
• By Dave Wallace

Amgen’s biosimilars sales are on the decline, largely due to erosion of its oncology portfolio. However, the debut of first US Humira rival Amjevita, along with planned versions of Stelara and Eylea, are expected to push the segment back into growth.

Wooden businessman down up stairs
As Amgen’s oncology biosimilars decline, a lift will come from new products • Source: Shutterstock

More from Biosimilars

More from Products